Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Pagano MB, Foroutan F, Goel R, Allen ES, Cushing MM, Garcia DA, et al. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB. Transfusion. 2022;62(8):1652-1661.

Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, et al. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022;20(5):673-685.

Leung W, Teater M, Durmaz C, Meydan C, Chivu AG, Chadburn A, et al. SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer Discov. 2022;12(7):1782-1803.

Devereaux KA, Souers RJ, Merker JD, Lindeman NI, Graham RP, Hameed MR, et al. Clinical Testing for Tumor Cell-Free DNA. Arch Pathol Lab Med. 2022.

Devereaux KA, Souers RJ, Graham RP, Portier BP, Surrey LF, Yemelyanova A, et al. Neoplastic Cellularity Assessment in Molecular Testing. Arch Pathol Lab Med. 2022;146(9):1062-1071.

Alilou M, Khorrami M, Prasanna P, Bera K, Gupta A, Viswanathan VS, et al. A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. Sci Adv. 2022;8(47):eabq4609.

Nickeleit V, Singh HK, Davis VG, Seshan SV. Classifying Polyomavirus Nephropathy: The "Banff" Initiative. Transpl Int. 2022;35:10299.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553.

Singhal S, Hellyer J, Ouseph MM, Wakelee HA, Padda SK. Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. JTO Clin Res Rep. 2022;3(5):100323.

Ullmann TM, Thiesmeyer JW, Lee YJ, Beg S, Mosquera JM, Elemento O, et al. RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype. Ann Surg Oncol. 2022.